UroToday1h
SUO 2024: Real-World Treatment and Clinical Outcomes in Patients with mCRPC Treated with Olaparib in the United States
Overall, the median real world time on treatment for earliest olaparib monotherapy 4.6 months (95% CI 3.5 - 5.5), for patients with less than 3 lines of therapy was 5.3 months (95% CI 4.0 – 8.2), and ...
UroToday2h
SUO 2024: E-cigarette Use and the Risk of Bladder Cancer
(UroToday.com) The 2024 SUO annual meeting included a session on smoking cessation, vaping, and e-cigarettes, featuring a presentation by Dr. Marc Bjurlin discussing e-cigarette use and the risk of ...
UroToday4h
SUO 2024: A Phase III Study of 177Lu-TLX591 plus Standard-of-Care Versus Standard-of-Care Alone in Patients with mCRPC (PROSTACT GLOBAL)
Dr. Scott Tagawa presented ProstACT GLOBAL, a phase III study of best SOC with or without 177 Lu-DOTA-rosopatamab (TLX591) for patients with PSMA-expressing mCRPC who experienced disease progression ...
UroToday10h
SUO 2024: A Personalized and Pragmatic Approach to (P)rehabilitation for Patients with Bladder Cancer
(UroToday.com)The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Course and the Session Muscle Invasive ...
UroToday1h
SUO 2024: Adjuvant Systemic Therapy in Urothelial Carcinoma: Where Are We At Today?
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to an Advanced Disease and Adjuvant Therapy session. Dr. Jean Hoffman-Censits discussed the ...
UroToday5h
SUO 2024: Adjuvant Radiation Following Cystectomy: Underutilized Therapy?
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to an Advanced Disease and Adjuvant Therapy session. Dr. Omar Mian discussed the role of adjuvant ...